Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 3 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 21 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
31 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Immunofusion from Charleroi, company number BE0804563629, closed financial year 2025 with a result of € -42,606 after tax. For that financial year Immunofusion recorded a gross margin of € -42,496 and equity of € -126,049. Compared with financial year 2024, the result moved from € -72,858 to € -42,606. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ -126,049
▼ € 42,606 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -42,606
▲ 42 % less loss than in 2024
Profit after tax over the fiscal year.
€ 22,275
▲ € 18,884 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -129,049.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 15,689
▲ € 14,963 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € -13,585 | € -72,670 | € -42,496 | ▲ € 30,174 |
| Profit after taxes | € -13,585 | € -72,858 | € -42,606 | ▲ € 30,252 |
| Equity | € -10,585 | € -83,443 | € -126,049 | ▼ € 42,606 |
| Total debts | € 12,847 | € 88,204 | € 158,180 | ▲ 79% |
| Cash | € 451 | € 3,391 | € 22,275 | ▲ € 18,884 |
| Retained profit | € -13,585 | € -86,443 | € -129,049 | ▼ € 42,606 |
| Balance sheet total | € 2,262 | € 4,761 | € 32,131 | ▲ € 27,370 |
Key figures of Immunofusion, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Immunofusion?
What happened at Immunofusion in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 42,606. Source: NBB ↗
- Anzhelika Yurieva became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 13,585 loss in 2023 to € 42,606 loss in 2025.
A new publication or filing at Immunofusion? We notify you, reason included.
Follow ImmunofusionDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Immunofusion are Anzhelika Yurieva and Aleksandra Bobkova-Rogatnikova.
Directors
According to the 2025 annual accounts
Anzhelika Yurieva
Director
since 2026
Aleksandra Bobkova-Rogatnikova
Director
Establishments
Establishment units
Physical locations of this company
Rue Clément Ader 10
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 31 companies are registered at this address.
All companies at this address →Brussels South Charleroi BioPark Dev
€ 80,186 gross margin · 2025
ImmunXperts
€ 393,338 gross margin · 2024
LYS MEDICAL
€ -309,203 gross margin · 2025
SPECTRALYS BIOTECH
€ 143,689 gross margin · 2025
ProtonW.be
€ -7,643 gross margin · 2025
+26 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0804.563.629
- VAT number
- BE 0804.563.629
- Registered office
- Rue Clément Ader 10, 6041 Charleroi
- Names & denominations
- Immunofusion
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 August 2023
- Peppol
- Active · Active since 28 Oct 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Speur- en ontwikkelingswerk op het gebied van de maatschappij- en geesteswetenschappen
Overige gespecialiseerde wetenschappelijke en technische activiteiten